Thinking through the multimodal treatment of localized oesophageal cancer: the point of view of the surgeon

Philip H. Pucher, Bas P.L. Wijnhoven, Timothy J. Underwood, John V. Reynolds, Andrew R. Davies*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


PURPOSE OF REVIEW: This review examines current developments and controversies in the multimodal management of oesophageal cancer, with an emphasis on surgical dilemmas and outcomes from the surgeon's perspective. RECENT FINDINGS: Despite the advancement of oncological neoadjuvant treatments, there is still no consensus on what regimen is superior. The majority of patients may still fail to respond to neoadjuvant therapy and suffer potential harm without any survival advantage as a result. In patients who do not respond, adjuvant therapy is still often recommended after surgery despite any evidence for its benefit. We examine the implications of different regimens and treatment approaches for both squamous cell cancer and adenocarcinoma of the oesophagus. SUMMARY: The efficacy of neoadjuvant treatment is highly variable and likely relates to variability of tumour biology. Ongoing work to identify responders, or optimize treatment on an individual patient, should increase the efficacy of multimodal therapy and improve patient outcomes.

Original languageEnglish
Pages (from-to)353-361
Number of pages9
JournalCurrent Opinion in Oncology
Issue number4
Publication statusPublished - 1 Jul 2021

Bibliographical note

Publisher Copyright:
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.


Dive into the research topics of 'Thinking through the multimodal treatment of localized oesophageal cancer: the point of view of the surgeon'. Together they form a unique fingerprint.

Cite this